Enveric Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENVB Nasdaq 2836 www.enveric.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enveric Biosciences, Inc.

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates - Mar 31st, 2026 6:00 am
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 - Mar 27th, 2026 3:40 pm
Enveric Biosciences Announces Registration of Five Trademarks - Mar 18th, 2026 6:00 am
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent - Feb 25th, 2026 6:00 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Feb 22nd, 2026 5:43 pm
Enveric Biosciences reports EB-003 receptor engagement assay data - Feb 20th, 2026 6:09 am
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data - Feb 19th, 2026 6:00 am
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option - Jan 29th, 2026 6:00 am
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Jan 28th, 2026 3:00 pm
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Jan 28th, 2026 6:00 am
Enveric Biosciences announces issuance of U.S. patent - Dec 30th, 2025 6:10 am
Enveric Biosciences Announces Patent Issuance - Dec 29th, 2025 6:00 am
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds - Dec 12th, 2025 2:46 pm
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds - Dec 11th, 2025 11:43 am
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates - Dec 9th, 2025 6:00 am
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026" - Dec 4th, 2025 6:00 am
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates - Nov 26th, 2025 6:00 am
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Nov 14th, 2025 2:05 pm
Enveric Biosciences Announces Reverse Stock Split - Oct 23rd, 2025 6:00 am
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance - Oct 16th, 2025 6:30 am